Kuno T, Ueyama H, Takagi H, et al. - In order to determine the effectiveness as well as safety of different antithrombotic strategies in patients with atrial fibrillation (AF) receiving percutaneous coronary intervention (PCI), researchers analyzed 5 eligible randomized trials including a total of 11,532 patients and comparing 9 treatment strategies. These trials were identified from PUBMED and EMBASE and reported the effectiveness and safety of various antithrombotic strategies in patients with AF who underwent PCI and/or acute coronary syndrome. Comparisons were performed between 9 antithrombotic strategies including combinations of vitamin K antagonist with dual antiplatelet therapy (DAPT) or P2Y₁₂ inhibitor, combinations of direct oral anticoagulants (DOAC) (apixaban, dabigatran, rivaroxaban, and edoxaban) with DAPT or P2Y₁₂ inhibitor (clopidogrel, prasugrel, and ticagrelor). Findings revealed that lowest bleeding occurred in relation to apixaban + P2Y₁₂ inhibitors vs other regimens including other DOACs + P2Y₁₂ inhibitors, with no increment in ischemic outcomes, among patients with AF undergoing PCI.